Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD [Phase 3]

View source ↗

Summary

A Phase 3 study completed evaluating the effectiveness and safety of LY03003 in patients with early primary Parkinson disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• LY03003

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED